Apimeds Pharmaceuticals US (APUS) Interest & Investment Income (2024 - 2025)

Apimeds Pharmaceuticals US (APUS) posted Interest & Investment Income of $35919.0 for Q4 2025, down 36.34% on a QoQ basis from $56426.0 in Q3 2025, and up 119630.0% year-over-year from N/an in Q4 2024.

Apimeds Pharmaceuticals US (APUS) Interest & Investment Income (2024 - 2025) Analysis & Trends

Apimeds Pharmaceuticals US's Interest & Investment Income history runs 2 years deep, the most recent figure standing at $35919.0 for Q4 2025.

  • Quarterly Interest & Investment Income rose 119630.0% year-over-year to $35919.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $107595.0 (up 3710.02% YoY) and the FY2025 annual result came in at $107595.0, up 3710.02% from the prior year.
  • Interest & Investment Income was $35919.0 for Q4 2025 at Apimeds Pharmaceuticals US, down from $56426.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $56426.0 in Q3 2025 and bottomed at $3.0 in Q1 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Int & Inv Inc (Qtr)
1 Haleon 89.28 Bn 87.42 Bn - -
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn -
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn -
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn 32.85 Mn
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn 41.80 Mn
6 RedHill Biopharma 22.11 Bn 22.11 Bn - -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn -
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn 28.10 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn -
10 Apimeds Pharmaceuticals US 62.67 Mn 62.67 Mn - 35,919.00

Historic Data

Download Data
DateValue
Dec 31, 2025 35,919.00
Sep 30, 2025 56,426.00
Jun 30, 2025 15,247.00
Mar 31, 2025 3.00
Dec 31, 2024 30.00
Sep 30, 2024 116.00
Jun 30, 2024 517.00
Mar 31, 2024 2,161.00